Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Diabetologia 65 , 18301838 (2022)
I think there's still
4 Whether oral semaglutide reduces the risk of MACE is currently being investigated in a larger and longer (3.5-5 years) CVOT, SOUL, estimated to complete in 2024
If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page and at /affiliate-disclosure.html
Martinez-Jimenez, M
Commonly reported side effects in the Phase 2 trial included: Nausea (the most frequently reported adverse effect) Vomiting Diarrhoea Constipation Decreased appetite Abdominal discomfort or bloating Eructation (belching) The majority of participants who discontinued treatment did so due to gastrointestinal side effects, underscoring the importance of the slow titration schedule used in trials
.jpg)
